# TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.

> **NCT07009184** · EARLY_PHASE1 · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 19 (estimated)

## Conditions studied

- HER2 Positive Solid Tumor

## Interventions

- **DRUG:** [111In]In-DOTA-TCO-trastuzumab
- **DRUG:** Small molecule tetrazine trigger component

## Key facts

- **NCT ID:** NCT07009184
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009184, "TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07009184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*